Research and Development on Lentivectors for:
Lentivectors have been first described in 1996. Since then, they are in constant evolution, in terms of efficiency and safety.
Lentivectors are now used in several clinical trials, including correction of severe genetic diseases or even as anti-HIV gene therapy.
Lentivectors are also highly versatile tools to create “novel” cell lines for research, diagnostic or therapeutic purposes.
Since 2005, we have developed at the UNIGE-LENTILAB, a panel of lentivectors with 2 main objectives:
Also, since 2015, we are developing an inducible HIV-derived lentivector producer cell line, for use in future gene therapy projects.
Although lentivectors are “relatively” easy to construct and produce, labs which are not familiar with the many technical aspects of lentivector production can benefit from expert advice as well as a repository of extensively characterized reagents.
This is why more and more big universities in the world now have in-house facilities that provide lentivector tools and services to their community, saving their scientists huge amounts of time, money and energy.
|Lentis Titration by FACS|
|Lentis Titration by qPCR|
|Design of efficient miRNAs|
|BSL-2 Emergency Procedures|
|BSL-2 Decontamination Procedures|
|Decontamination of Liquid Nitrogen Tanks|